Dornase alfa for cystic fibrosis

Area of Science:

• Pulmonary Medicine
• Pharmacology
• Genetic Disorders

Background:

• Dornase alfa is a mucolytic agent used in cystic fibrosis (CF) to reduce mucus viscosity and improve airway clearance.
• Pulmonary disease is the primary cause of morbidity and mortality in CF patients.
• This review updates previous findings on dornase alfa's efficacy and safety in CF management.

Purpose of the Study:

• To evaluate the impact of dornase alfa on mortality and morbidity in cystic fibrosis patients compared to placebo or alternative airway clearance medications.
• To identify and assess adverse events associated with dornase alfa therapy in CF.

Main Methods:

• A systematic review of randomized and quasi-randomized controlled trials was conducted.
• Searches included the Cochrane Cystic Fibrosis and Genetic Disorders Group Trials Register, ClinicalTrials.gov, and the International Clinical Trials Registry Platform.
• Trials compared dornase alfa against placebo, standard therapy, or other airway clearance agents; data extraction and quality assessment were performed independently.

Main Results:

• Dornase alfa likely improved forced expiratory volume in one second (FEV1) at various time points up to two years compared to placebo (moderate to high-quality evidence).
• The number of pulmonary exacerbations was probably reduced with dornase alfa therapy over trials up to two years (moderate-quality evidence).
• Adverse events such as voice alteration and rash were reported more frequently with dornase alfa, but overall safety was comparable to other treatments.

Conclusions:

• Dornase alfa therapy demonstrates potential to improve lung function and decrease pulmonary exacerbations in cystic fibrosis patients over one month to two years.
• Voice alteration and rash are the primary adverse events associated with dornase alfa.
• Insufficient evidence exists to definitively establish dornase alfa's superiority over other hyperosmolar agents for improving lung function.